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Introduction
Atrial fibrillation (AF) is the most common arrhythmia in clinical 
practice, and is associated with increased morbidity and mortality.1-3) 
Due to the fact that AF increases with advancing age, many studies 
suggest an increasing prevalence and incidence of AF, predicting 
that it will increase to 15.9 million by 2050, with more than half 
of all patients ≥80 years of age.4-9) Consequently, the economic 
burden associated with AF is increasing considerably, and is mainly 
driven by hospital visits, including hospitalizations and outpatient 
clinic visits.10) This public health burden is reported to be 1% of the 
National Health Service budget in the United Kingdom, estimated 
to be 16 to 26 billion dollars In United States.11-13) Therefore, the 
understanding of the trend in AF-related hospital cost is critical 
for healthcare planning and for reducing demands on the health 
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insurance system.
South Korea is becoming an ageing society, and 7.2% of the 
total population was aged 65 years or older in 2000. Furthermore, 
the aging population is rapidly increasing, and it is expected that 
a quarter of the total population to be ≥65 years of age by 2030 
(Statistics Korea. Korea statistical yearbook. http://kostat.go.kr/
portal/english/index.action). However, there is paucity of data on 
AF incidence, prevalence, hospital cost and treatment patterns in 
South Korea, as well as other Asian countries. We sought to evaluate 
1) the number of total and newly diagnosed AF individuals, 2) the 
burden of AF-related hospital visits and costs, 3) treatment patterns 
including medications and catheter ablation, and 4) morbidity and 
mortality, especially for cardiovascular disease and stroke related 
death using the South Korean National Health Insurance sample 
cohort population from 2004 to 2013.
Subjects and Methods
Data sources
National Health Insurance (NHI) is the single insurer managed by 
the Korean government; about 97% of the Korean population are 
mandatory subscribers and the remaining 3% of the population 
are medical Aid subjects. Based on this NHI database, the Korean 
National Health Insurance Dataset Sample Cohort (K-NHID-Sample 
Cohort) was created and released in 2014, and contains 1025340 
individuals representing the total Korean population from its start 
in 2002, amounting to 2.2% of the entire population in the Korean 
National Health insurance Service, up until 2013. Because there 
were some dropouts due to death, some newborn cases were 
added each year to balance its dropouts and maintain consistent. 
Study population
This observational cohort study using the NHID-cohort included 
a total of 819948 patients at ≥15 years of age from 2004-December 
2013. Among this group, patients with AF were identified with 
Korean Classification of Disease 6th Revision (KCD-6) codes, which 
are codes from a validated modified classification system from the 
International Classification of Disease 10th Revision (ICD-10) codes, 
I48 (atrial fibrillation and atrial flutter), I48.0 (atrial fibrillation), and 
I48.1 (atrial flutter). We regarded the first date of receiving AF-
related KCD-6 codes as a newly diagnosed year, and excluded the 
first 2 years (2002 to 2003) to avoid the possibility for misdiagnosis 
of preexisting AF for an incident of AF. Moreover, we defined 
patients with AF only when AF was a hospital discharge diagnosis 
or was confirmed on at least 2 visits in the outpatient clinic.14)15)
Patients’ medical records and KCD-6 diagnosis codes were 
reviewed for information on age, gender, and comorbidities 
included in CHA2DS2-VASc (I50 for Congestive heart failure, I10, 
I11, I12, and I14 for hypertension, E10, E11, E12, E13, and E14 for 
Diabetes mellitus, I63, I64, and G45 for prior Stroke or transient 
ischemic attack, I21, I252, I65, I70, I71, I72, and I73 for Vascular 
disease) score.
Treatment patterns and outcome measurement
We included all AF patients ≥15 years of age and were followed 
for 10 years from 2004 to 2013.  They were analyzed in terms of 
treatment patterns including medication for stroke prevention, 
rate control, rhythm control, and radiofrequency catheter ablation 
(RFCA). We only counted medications prescribed more than 3 
months. Clinical outcomes assessed in this study included ischemic 
stroke-related admission, bleeding event-related admission 
including brain and gastrointestinal tract, all cause death, 
cardiovascular death, and stroke-related death for each case with 
the use of KCD-6 codes.
Statistical analysis
Descriptive statistics were used to characterize trends of AF-
related hospitalization, out-patient clinic visits, hospital costs, 
incidence, prevalence, morbidity, mortality and treatment patterns. 
Pearson chi-square tests were used to describe the relationship 
between variables. Annual p for trend was determined by 
Wilcoxon-type test for trend across ordered groups. All tests were 
two-tailed, with p<0.05 considered significant. Statistical analysis 
was performed using The Statistical Package for the Social Sciences 
(SPSS 23.0; SPSS Inc., Chicago, IL, USA) and statistical software R 
package (R 3.2.3; R studio, Boston, MA, USA).
Results
Trend of hospitalizations and outpatient visit for AF
Table 1 shows the number of total patients with AF and the 
number of patients newly diagnosed with AF each year. In 2004, the 
number of patients with AF was 4197, and the estimated prevalence 
rate was 0.51%. In 2013, the prevalence rates progressively 
increased 2.69-fold between 2004 and 2013, and reached 1.38%.
In the period from 2004 to 2013, all comorbidities included in 
CHADS2 and CHA2DS2-VASc scores increased within one decade, 
thus the risk of stroke as determined by the mean CHADS2 score 
increased from 2.28 to 2.91, and the mean CHA2DS2-VASc score 
increased from 3.51 to 4.42 in the total AF population (p<0.001, 
Table 1). 
The number of hospitalizations per year increased 2.19-fold (1,120 
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to 2,451, p<0.001, Table 2, Fig. 1B), and the number of outpatient 
clinic visits had a 3.06-fold increase from 9847 in 2004 to 30150 
in 2013 (p<0.001, Table 2, Fig. 1B). The number of mean hospital 
visits per patient/year showed no significant change for the decade 
(Fig. 1C).
Trends in hospital cost for AF
During the 10-year follow-up, total medical cost, which 
consisted of hospitalization costs and outpatient clinic visit costs 
progressively increased (p<0.001, Table 2, Fig. 2A). Hospitalization 
costs increased from 3.6 billion (won) in 2004 to 11.3 billion (won) 
in 2013 (p<0.001), and outpatient clinic visit costs increased 
from 0.3 billion (won) to 1.0 billion (won) in the same time frame 
(p<0.001. While the total medical cost increased for the decade, 
mean medical cost per patient/year also increased from 0.68 million 
(won) to 0.83 million (won) (p<0.001.  This was mainly due to the 
increase of mean hospitalization costs per patient/year (Fig. 2B).
Stroke risk and management
Patients’ distribution according to CHA2DS2-VASc scores is 
presented in Fig. 3. The proportion of patients with CHA2DS2-VASc 
score ≥2 increased from 82.8% to 88.9% from 2004 to 2013. 
Although stroke risk for each patient increased annual according 
to the increase of CHADS2 and CHA2DS2-VASc scores, the 
proportion of patients with anticoagulation with warfarin showed 
no significant change from 2004 to 2013, and the proportion of 
patients who took aspirin showed no significant changes in the 
same time frame (Table 3, Fig. 4A). This trend was consistent among 
patients with CHA2DS2-VASc score ≥2 (Fig. 4B). The proportion of 
patients who took antiplatelet agents other than aspirin showed a 
Table 1. Baseline characteristics of the patients with atrial fibrillation as the principal diagnosis per 1 million Korean population
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Total AF population*
4197
(0.51)
5219
(0.63)
6107
(0.74)
7029
(0.83)
7986
(0.96)
8780
(1.05)
9614
(1.14)
10502
(1.23)
11301
(1.31)
11993
(1.38)
New AF population
1328
(0.16)
1301
(0.16)
1200
(0.15)
1255
(0.15)
1347
(0.16)
1214
(0.15)
1267
(0.15)
1397
(0.15)
1354
(0.16)
1301
(0.15)
Male
2214
(52.8)
2742
(52.5)
3204
(52.5)
3688
(52.5)
4217
(52.8)
4595
(52.3)
5033
(52.4)
5479
(52.2)
5892
(52.1)
6271
(52.3)
Age
15-29
140
(3.4)
174
(3.4)
211
(3.5)
255 
(3.7)
308
(3.9)
347
(4.0)
378
(4.0)
412
(3.9)
447
(4.0)
463
(3.9)
30-44
391
(9.3)
520
(10.0)
611
(10.0)
728
(10.4)
830
(10.4)
922
(10.5)
992
(10.3)
1092
(10.4)
1177
(10.4)
1259
(10.5)
45-59
1041
(24.8)
1320
(25.3)
1599
(26.2)
1809 
(25.7)
2084
(26.1)
2305
(26.3)
2559
(26.6)
2778
(26.5)
3027
(26.8)
3245
(27.1)
60-74
1883
(44.9)
2273
(43.6)
2632
(43.1)
3003
(42.7)
3373
(42.2)
3680
(41.9)
3985
(41.5)
4304
(41.0)
4578
(40.5)
4820
(40.2)
>75
742
(17.7)
932
(17.9)
1054
(17.3)
1234
(17.6)
1391
(17.4)
1526
(17.4)
1700
(17.7)
1916
(18.2)
2072
(18.3)
2206
(18.4)
Comorbidities
HTN* 3393(80.4)
4296
(82.3)
5082
(83.2)
5861
(83.4)
6683
(83.4)
7399
(83.7)
8128
(84.5)
8922
(85.0)
9711
(85.9)
10334
(86.2)
DM*
1817
(43.3)
2512
(48.1)
3176
(52.0)
3884
(55.3)
4606
(57.7)
5279
(60.1)
6014
(62.6)
6725
(64.0)
7550
(66.8)
8252
(68.8)
HF*
1631
(38.9)
2045
(39.2)
2389
(39.1)
2713
(38.6)
2973
(37.2)
3263
(37.2)
3614
(37.6)
4058
(38.6)
4456
(39.4)
4851
(40.4)
Stroke*
1012
(24.1)
1369
(26.2)
1762
(28.9)
2164
(30.8)
2632
(33.0)
3025
(34.5)
3420
(35.6)
3835
(36.5)
4217
(37.3)
4620
(38.5)
CHADS2 score* 2.28 2.40 2.49 2.56 2.62 2.68 2.74 2.79 2.85 2.91
CHA2DS2-VASc score* 3.51 3.67 3.79 3.90 3.99 4.09 4.18 4.26 4.34 4.42
Values are presented as number (%).*p value for trends <0.05. AF: atrial fibrillation, HTN: hypertension, DM: diabetes mellitus, HF: heart failure
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modest increase in the same time frame (p<0.05 for trends, Table 3). 
Rhythm and rate control of AF
Table 3 shows the trends of AF treatment with medication or 
RFCA. The use of beta-blockers (BB) showed a significant increase 
(22.6% to 27.1%, p<0.001 for trends), whereas calcium channel 
blocker (CCB) showed no significant changes during the decade. 
The use of digoxin significantly decreased from 23.4% in 2004 to 
11.4% in 2013 (p<0.001). 
The total use of anti-arrhythmic drugs (AADs), including Class Ic 
and Class III AADs showed a slight increase for the decade (6.8% 
to 7.6%, p<0.05 for trends), even though the use of class III drugs 
decreased (4.3% to 3.2%, p<0.05 for trends). The proportion of 
hospitalization for RFCA in the total number of hospitalizations 
showed an increase from 0.43 % in 2004 to 1.09 % in 2013 
(p<0.001). 
Morbidity and mortality of AF
Ischemic stroke-related admissions and bleeding events related 
admissions, including GI bleeding and cerebral hemorrhage, showed 
no significant changes from 2004 to 2013 (Table 4). However, All-
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Fig. 1. According to the progressive increase in the prevalence of AF, the number of hospitalizations and the number of outpatient clinic visits had the 
progressive increase from 2004 to 2013. (A) Trends of the number of AF population, (B) hospital visit, and (C) mean number of hospital visit per patient/year. 
AF: afrial fibrillation.
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Table 2. The number of hospital visit and medical cost
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Hospitalization 1120 1316 1317 1449 1599 1663 1744 2002 2301 2451
Total hospitalization cost* † 
(USD)
360.92
(330331)
466.20
(426689)
539.52
(493795)
628.61
(575334)
766.00
(701080)
831.39
(760928)
862.37
(789282)
1072.88
(981951)
1174.50
(1074959)
1127.11
(1031585)
Hospitalization duration 16.23 16.26 17.46 19.24 19.75 20.81 21.89 22.28 24.06 19.67
Mean cost per hospitalization* † 
(USD)
3.22
(2947)
3.54
(3240)
4.10
(3753)
4.34
(3972)
4.79
(4384)
5.00
(4576)
4.94
(4521)
5.36
(4906)
5.10
(4668)
4.60
(4210)
Outpatient clinic visit*, n 9847 11186 11915 14049 15919 17415 18654 21060 27272 30150
Total outpatient clinic visit cost* † 
(USD)
313.86
(287250)
401.54
(367496)
453.71
(415243)
529.06
(484205)
506.19
(463274)
638.11
(584009)
775.57
(709815)
765.28
(700398)
923.42
(845130)
986.82
(903155)
Mean number of clinic visit per 
patient/year
2.3 2.1 2.0 2.0 2.0 2.0 1.9 2.0 2.4 2.5
Mean cost per clinic visit, 
(USD)
34843
(31.9)
38759
(35.5)
39756
(36.4)
36075
(33.0)
33248
(30.4)
38402
(35.1)
42698
(39.1)
36837
(33.7)
34453
(31.5)
33614
(30.8)
All costs were calculated in Korean won (KRW), and converted into US dollars (USD) (1 USD=1092.64 KRW). *p value for trends <0.05. †Million won (₩)
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cause mortality (6.7% to 5.0%, p<0.001), cardiovascular mortality 
(1.4% to 1.1%, p<0.001) and stroke-related death (1.3% to 0.8%, 
p<0.001) showed a modest decrease from 2004 to 2013 (Table 4).
Discussion
The main finding of this study is that during the last decade, AF-
Table 3. Trends of AF patients according to treatment patterns, morbidity and mortality
Medications
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Stroke prevention
Aspirin
1359
(32.4)
1757
(33.7)
2051
(33.6)
2411
(34.3)
2689
(33.7)
2928
(33.3)
3197
(33.3)
3498
(33.3)
3769 
(33.4)
3868
(32.3)
Other antiplatelet agents* † 
148
(3.5)
194
(3.7)
280
(4.6)
445
(6.3)
608
(7.6)
805
(9.2)
833
(8.7)
953
(9.1)
1147
(10.1)
1361
(11.3)
Warfarin
764
(18.2)
934
(17.9)
1034
(16.9)
1151
(16.4)
1256
(15.7)
1381
(15.7)
1476
(15.4)
1679
(16.0)
1863
(16.5)
2002
(16.7)
Rate control
Beta blocker*
948
(22.6)
1241
(23.8)
1465
(24.0)
1694
(24.1)
1889
(23.7)
2112
(24.1)
2393
(24.9)
2736
(26.1)
3034
(26.8)
3248
(27.1)
Calcium channel blocker*
322
(7.7)
383
(7.3)
452
(7.4)
536
(7.6)
598
(7.5)
654
(7.4)
673
(7.0)
780
(7.4)
830
(7.3)
914
(7.6)
Digoxin*
980
(23.4)
1121
(21.5)
1153
(18.9)
1194
(17.0)
1170
(14.7)
1219 
(13.9)
1206
(12.5)
1327
(12.6)
1351
(12.0)
1367
(11.4)
Rhythm control
Number of patients*
287
(6.8)
333
(6.4)
402
(6.6)
453
(6.4)
499
(6.2)
570
(6.5)
602
(6.3)
745
(7.1)
819
(7.2)
916
(7.6)
Class Ic*
116
(2.8)
146
(2.8)
190
(3.1)
224
(3.2)
263
(3.3)
301
(3.4)
324
(3.4)
418
(4.0)
483
(4.3)
566
(4.7)
Class III*
180
(4.3)
201
(3.9)
224
(3.7)
247
(3.5)
257
(3.2)
285
(3.2)
295
(3.1)
349
(3.3)
359
(3.2)
378
(3.2)
Hospitalization for RFCA‡ 5 (0.43) 4 (0.30) 7 (0.01) 3 (0.20) 17 (1.01) 19 (1.11) 26 (1.41) 19 (0.85) 43 (1.71) 30 (1.09)
Values are presented as number (%).  *p value for trends <0.05. †Includes clopidogrel, prasugrel, and ticagrelor. ‡Estimated by the proportion of hospitaliza-
tion for RFCA out of total hospitalization number. RFCA: radiofrequency catheter ablation
Table 4. Clinical outcomes
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Stroke related admission
193
(4.6)
210
(4.0)
248
(4.1)
275
(3.9)
35
(4.5)
344
(3.9)
336
(3.5)
396
(3.8)
409
(3.6)
518
(4.3)
GI bleeding related admission
38
(0.9)
50
(1.0)
49
(0.8)
49
(0.7)
69
(0.9)
72
(0.8)
66
(0.7)
85
(0.8)
103
(0.9)
109
(0.9)
Cerebral hemorrhage related 
admission
48
(1.1)
51
(1.0)
75
(1.2)
85
(1.2)
109
(1.4)
109
(1.2)
99
(1.0)
126
(1.2)
137
(1.2)
145
(1.2)
All-cause mortality*
279
(6.7)
312
(6.0)
333
(5.5)
390
(5.6)
420
(5.3)
433
(4.9)
509
(5.3)
555
(5.3)
609
(5.4)
602
(5.0)
Cardiovascular mortality*
60
(1.4)
67
(1.3)
87
(1.4)
102
(1.5)
90
(1.1)
90
(1.0)
104
(1.1)
128
(1.2)
134
(1.2)
129
(1.1)
Stroke-related mortality*
53
(1.3)
56
(1.1)
53
(0.9)
61
(0.7)
59
(0.9)
75
(0.9)
85
(0.9)
95
(0.9)
78
(0.7)
94
(0.8)
Values are presented as number (%). All outcome events were estimated as the proportion of patients among AF population. *p value for trends <0.05. 
GI: gastrointestinal, AF: atrial fibrillation
61Hancheol Lee, et al.
https://doi.org/10.4070/kcj.2016.0045www.e-kcj.org
related hospitalizations and outpatient clinic visits have increased 
with the increase of comorbidities. Second, although catheter 
ablation increased, the rate of anticoagulation did not improved. 
Although mortality in patients with AF showed a modest decrease 
from 2004 to 2013, proper anticoagulation therapy is warranted 
for the improvement of public health.
This investigation reports serial data of AF hospital visits over a 
10-year period in South Korea with the use of 1 million population 
of Korean National Health Insurance Dataset Sample Cohort (NHID-
Sample Cohort). Moreover, this is the first observational study to 
investigate hospital visits and hospital costs, treatment patterns, 
morbidity, and mortality of AF in this nation-wide semi-dynamic 
cohort. 
Hospital cost
As expected, from 2004 to 2013, the number of patients with 
prevalent AF (3.64-fold) and the number of hospitalizations per year 
(2.19-fold) significantly increased. Consequently, the total hospital 
cost per year (256%) and mean medical cost per patient/year 
(22%) showed a consistent increase for the 10-year follow-up. 
Consistent with our findings, many previous studies have shown 
that the number of AF-related hospitalizations, outpatient clinic 
visits and hospital costs increased with the aging population and 
more prevalent risk factors such as hypertension and diabetes.16)17) 
The aging population, with many other comorbidities, is rapidly 
increasing and it is expected that a quarter of the total population 
will be ≥65 years of age by 2030 in South Korea subsequently 
exponentially increasing AF-related medical costs.  Moreover, the 
number of RFCA shows a consistent increase for the decade, which 
could contribute to the rise of hospital costs. Therefore, long-term 
healthcare planning for reducing demands on NHI is warranted for 
the next decade and beyond. 
Trends in treatment patterns
Many studies have reported that the underuse of anticoagulation 
therapy increases with age,18)19) and a previous study reported 
that only 35% of patients aged >85 years of age receive 
anticoagulation.20) In this study, although the mean CHA2DS2-VASc 
score of the AF population increased from 3.5 to 4.4, the proportion 
of patients who received oral anticoagulation with warfarin did 
not show an increase, and even uses of aspirin did not show any 
changes for the decade. Moreover, this trend was also found in 
patients with CHA2DS2-VASc score ≥2, which indicates a high 
stroke risk and indication for anticoagulation. It is likely due to the 
Fig. 3. Patients’ distribution according to CHA2DS2-VASc score.
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deep concerns physicians have for the aging patient population. 
Since anticoagulation therapy for elderly AF patients could safely 
and efficiently be used compared to aspirin,21) education about 
anticoagulation at the national-level should be considered as a 
goal to improve awareness and public health. Moreover, a decrease 
in digoxin use for the decade could have an important clinical 
implication, because recent studies have shown adverse effects of 
digoxin as a rate-control drug and increased mortality of the AF 
population.15)22) 
Mortality in AF
Previous studies have reported that global burden and AF 
associated mortality have increased exponentially.23)24) However, 
patients with AF in this national sample cohort population showed 
modest decrease of all-cause mortality, cardiovascular mortality 
and stroke-related death at the 10-year follow-up. Although 
it is unclear whether this result would be derived from proper 
rate control with the increase of beta blockers and decrease of 
digoxin use15)22) or if improvement in general medical care and 
the proportion of patients receiving anticoagulation therapy in 
patients with high stroke risk could further improve morbidity and 
mortality. Further analysis with the entire South Korean population 
is warranted for confirming these results. 
Limitations
This study was a retrospective observational study that was 
performed as a nationwide sample cohort data. Because the study 
population is the semi-dynamic cohort with 10-year follow-up, 
comorbidities and demographic data of patients cannot accurately 
represent those of the general population as years go by. However, 
on the other hand, this cohort can show the effect of aging on a 
patient of AF after a 10-year follow-up. All patients with AF were 
identified according to their diagnosis, not electrocardiogram; 
patients with atrial flutter were also included in the AF population. 
However, the co-existence of AF in patients with atrial flutter 
has reported to have increased by 50% in previous studies, and 
international guidelines suggest that an atrial flutter should 
be anticoagulated with the same protocol as AF.1)25)26) Because 
recurrent events such as second or third stroke could not be 
assessed by the use of the diagnosis code, we used the number of 
strokes and bleeding related admissions instead of actual events. 
Therefore, an underestimated comparison to real-world incident 
event rates could have occurred and therefore may not represent 
real world event rates.
In conclusion, during the last decade, hospital visits and costs 
for AF have increased exponentially among South Korea adults, 
and the proportions of comorbid chronic diseases and patients ≥75 
years of age have also increased significantly in the AF population. 
The trend of treatment patterns have shown significant changes, 
especially in the increase of beta blocker use, anti-arrhythmic drug 
use and RFCA, and decrease of digoxin use whereas the proportion 
of patients who received proper anticoagulation therapy showed 
no increase. Although all-cause mortality, cardiovascular mortality, 
and stroke-related mortality in patients with AF showed a modest 
decrease for the last decade, and the long-term plan at the NHI 
level for reducing AF-related medical cost, such as national-level 
education for proper anticoagulation therapy, are warranted for 
the improvement of public health.
40
30
20
10
0
Year
Total population
Pr
op
or
tio
n 
of
 p
at
ie
nt
s (
%
)
Warfarin
Aspirin
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
40
30
20
10
0
Year
Patients with CHA2DS2-VASc score ≥2
Pr
op
or
tio
n 
of
 p
at
ie
nt
s (
%
)
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
Warfarin
Aspirin
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